natgillin/translations-raw huggingface dataset:
• non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin when the patient cannot have surgery or radiotherapy. 
• nedrobnoceličnega pljučnega raka, pri katerem se uporablja kot zdravilo prve izbire v kombinaciji z zdravilom proti raku, imenovanim karboplatin, pri bolnikih, pri katerih kirurški poseg ali obsevanje nista primerna.
Abraxane is given into a vein over a period of 30 minutes. 
Zdravilo Abraxane se 30 minut infundira v veno.
In non-small cell lung cancer, 33% of patients receiving Abraxane and carboplatin responded to treatment compared with 25% of those receiving conventional paclitaxel and carboplatin. 
Pri nedrobnoceličnem raku pljuč se je na zdravljenje odzvalo 33 % bolnikov, ki so prejemali kombinacijo zdravila Abraxane in karboplatina, v primerjavi s 25 % bolnikov, ki so prejemali kombinacijo standardnega zdravila, ki vsebuje paklitaksel, in karboplatina.
Abraxane is a powder that is made up into a suspension for infusion (drip) into a vein. 
Zdravilo Abraxane je prašek za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
In metastatic breast cancer, Abraxane was more effective than conventional paclitaxel-containing medicines. 
Pri metastatskem raku dojk je bilo zdravilo Abraxane učinkovitejše od standardnih zdravil, ki vsebujejo paklitaksel.
Abraxane given on its own was compared with a conventional paclitaxel-containing medicine given together with other medicines to reduce side effects. 
Zdravilo Abraxane so kot samostojno zdravilo primerjali s standardnim zdravilom, ki vsebuje paklitaksel in se daje skupaj z drugimi zdravili za zmanjšanje neželenih učinkov.
In metastatic adenocarcinoma of the pancreas Abraxane is given in 4-week treatment cycles. 
Pri metastatskem adenokarcinomu trebušne slinavke se zdravilo Abraxane daje v štiritedenskih ciklih zdravljenja.
In metastatic adenocarcinoma of the pancreas, Abraxane was shown to improve overall survival. 
Pri metastatskem adenokarcinomu trebušne slinavke je zdravilo Abraxane izboljšalo skupni čas preživetja.
For the full list of restrictions with Abraxane, see the package leaflet. 
Za celoten seznam omejitev pri uporabi zdravila Abraxane glejte navodilo za uporabo.
For the full list of all side effects reported with Abraxane, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Abraxane, glejte navodilo za uporabo.
For non-small cell lung cancer, the Abraxane-carboplatin combination was compared with a combination of a conventional paclitaxel-containing medicine and carboplatin in 1,052 patients. 
Pri nedrobnoceličnem pljučnem raku so kombinacijo zdravila Abraxane in karboplatina pri 1 052 bolnikih primerjali s kombinacijo standardnega zdravila, ki je vsebovalo paklitaksel, in karboplatina.
In metastatic breast cancer Abraxane is given on its own every three weeks. 
Pri metastatskem raku dojk se zdravilo Abraxane vsake tri tedne daje kot samostojno zdravilo.
How does Abraxane work? 
Kako zdravilo Abraxane deluje?
What is Abraxane used for? 
Za kaj se zdravilo Abraxane uporablja?
What is Abraxane? 
Kaj je zdravilo Abraxane?
How has Abraxane been studied? 
Kako je bilo zdravilo Abraxane raziskano?
How is Abraxane used? 
Kako se zdravilo Abraxane uporablja?
In contrast, Abraxane was more effective than conventional paclitaxel-containing medicines in patients who had taken other treatments for metastatic breast cancer before. 
Za razliko od tega pa je bilo zdravilo Abraxane pri bolnicah, ki so že bile zdravljene zaradi metastatskega raka dojke, učinkovitejše od standardnih zdravil, ki vsebujejo paklitaksel.
Treatment may be repeated for up to five consecutive days. 
Zdravljenje lahko ponovite največ 5 zaporednih dni.
No data have been presented on overdoses in adult cats. 
Podatki o prevelikem odmerjanju pri odraslih mačkah niso bili predloženi.
Maropitant is effective against vomiting. 
Maropitant je učinkovit proti bruhanju.
Use only according to the benefit-risk assessment by the responsible veterinarian. 
Uporabljajte le v skladu z oceno koristi in tveganja odgovornega veterinarja.
Comment: Given the small vial size(s), would it not be preferable to replace these by “SC, IV" 
Pripomba: Glede na to, da so viale majhne, bi jih bilo morda bolje nadomestiti s s.c., i.v.
11.1 mg For the full list of excipients, see section 6.1. 
11,1 mg Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Use only according to the benefit-risk assessment by the responsible veterinarian, because conclusive reproductive toxicity studies have not been conducted in any animal species. 
Uporabite le v skladu z oceno razmerja korist/tveganje odgovornega veterinarja, saj dokončne raziskave reprodukcijske toksičnosti niso bile izvedene pri nobeni živalski vrsti.
• For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine. 
• Za preprečevanje perioperativne navzeje in bruhanja ter za izboljšanje okrevanja po splošni anesteziji po uporabi agonista opioidnega receptorja μ morfina.
MANUFACTURER'S BATCH NUMBER Lot: 
PROIZVAJALČEVA ŠTEVILKA SERIJE Lot:
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. 
Če opazite kakršne koli neželene učinke, ki niso navedeni v tem navodilu za uporabo, ali menite, da zdravilo ni bilo učinkovito, obvestite svojega veterinarja.
For subcutaneous or intravenous use in dogs and cats. 
Za subkutano ali intravensko uporabo pri psih in mačkah.
Injecting the product at refrigerated temperature may reduce pain at injection. 
Injiciranje zdravila, ohlajenega na temperaturo v hladilniku, lahko zmanjša bolečino med injiciranjem.
• For the treatment of vomiting, in combination with other supportive measures. 
• Za zdravljenje bruhanja, v kombinaciji z ostalimi podpornimi terapijami
Although maropitant has been demonstrated to be effective in both the treatment and prevention of emesis induced by chemotherapy, it was found more efficacious if used preventively. 
Čeprav je bilo dokazano, da je maropitant učinkovit pri zdravljenju in preprečevanju slabosti zaradi kemoterapije, je bilo ugotovljeno, da je bolj učinkovit pri preventivi.
In cats, moderate to severe response to injection is very commonly observed (in approximately one third of cats). 
Pri mačkah so zelo pogosto opazili zmeren do hud odziv na injiciranje (pri približno tretjini mačk).
This centre consists of several brainstem nuclei (area postrema, nucleus tractus solitarius, dorsal motor nucleus of the vagus) that receive and integrate sensory stimuli from central and peripheral sources and chemical stimuli from the circulation and the cerebro-spinal fluid. 
Center je sestavljen iz več možganskih jeder (area postrema, nucleus tractus solitarius, dorzalno motorično jedro vagusa), ki sprejemajo in povezujejo senzorične dražljaje centralnega in perifernega izvora in kemične dražljaje iz obtoka in cerebrospinalne tekočine.
In very rare cases, anaphylactic type reactions (allergic oedema, urticaria, erythema, collapse, dyspnoea, pale mucous membranes) may occur. 
V zelo redkih primerih se lahko pojavijo anafilaktični tipi reakcij (alergijski edem, urtikarija, eritem, kolaps, dispneja, blede mukazne membrane).
Excipients: Benzyl alcohol (E1519) 
Pomožne snovi: benzilalkohol (E1519)
Betadex sulfobutyl ether sodium Benzyl alcohol (E1519) Citric acid, anhydrous Sodium hydroxide Water for injections 
Seznam pomožnih snovi betadeks natrijev sulfobutil eter benzilalkohol (E1519) citronska kislina, brezvodna natrijev hidroksid voda za injekcije
11.1 mg A clear, colourless to light yellow solution. 
11,1 mg bistra, brezbarvna do svetlo rumena raztopina
Due to the frequent occurrence of transient pain during subcutaneous injection, appropriate animal restraining measures may have to be applied. 
Zaradi pogostega pojava prehodne bolečine med subkutanim injiciranjem bo morda potrebno žival ustrezno obvladati.
Dogs and cats. 
Psi in mačke
During clinical studies maropitant plasma levels conferred efficacy from 1 hour after administration. 
Med kliničnimi raziskavami je plazemski nivo maropitanta pokazal učinkovitost 1 uro po dajanju.
Pack sizes of 1 vial of 10 ml, 20 ml, 25 ml or 50 ml. 
Velikosti pakiranja: po 1 viala po 10 ml, 20 ml, 25 ml ali 50 ml.
Increases of approximately 10% in the QT interval of the ECG were observed in a study on healthy Beagle dogs administered 8 mg/kg orally; however, such an increase is unlikely to be of clinical significance. 
Približno 10-odstotno povečanje QT intervala ECG so opazili v raziskavi na zdravih psih beaglih, ki so jim aplicirali 8 mg/kg, vendar pa naj tako povečanje ne bi imelo kliničnega pomena.
Vomiting is a complex process coordinated centrally by the emetic centre. 
Bruhanje je kompleksen proces, ki ga uravnava center za bruhanje.
To be supplied only on veterinary prescription. 
Se izdaja samo na veterinarski recept.
The elimination t1/2 following intravenous dosing was approximately 5.8 h. 
Razpolovni čas izločanja t1/2 po intravenskem odmerjanju je bil približno 5,8 h.
By inhibiting the binding of substance P within the emetic centre, maropitant is effective against neural and humoral (central and peripheral) causes of vomiting. 
Z inhibicijo vezave substance P v centru za bruhanje maropitant učinkuje proti nevralnim in humoralnim (centralnim in perifernim) vzrokom bruhanja.
Manufacturer responsible for batch release: Produlab Pharma B.V. 
Proizvajalec zdravila, odgovoren za sproščanje serij: Produlab Pharma B.V.
In the case of accidental eye exposure, flush the eyes with plenty of water and seek medical attention. 
V primeru nenamernega stika z očmi sperite z obilo vode in poiščite zdravniško pomoč.
Maropitant is a neurokinin 1 (NK1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family. 
Maropitant je antagonist nevrokinin 1 (NK1) receptorja, ki zavira vezavo substance P, tahikininskega nevropeptida.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
DATUM ZADNJE ODOBRITVE NAVODIL ZA UPORABO Podrobne informacije o tem zdravilu so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) http://www.ema.europa.eu.
Signs of nausea in dogs including excessive salivation and lethargy might remain after treatment. 
Znaki navzee pri psih, kot sta povečano slinjenje in letargija, so lahko prisotni tudi po zdravljenju.
For administration by subcutaneous injection, see also “special precautions for use in animals” (section 4.5). 
Za dajanje s subkutano injekcijo glejte tudi poglavje 4.5 Posebni previdnostni ukrepi za uporabo pri živalih.
Products such as Prevomax should be used in conjunction with other supportive measures such as dietary control and fluid replacement therapy, as recommended by your veterinary surgeon. 
Zdravila, kot je Prevomax, naj bi uporabljali v povezavi z ostalimi podpornimi terapijami, kot je kontrolirana dieta in terapija z nadomeščanjem tekočin, po priporočilu vašega veterinarja.
Shelf life after first opening the vial: 56 days. 
Rok uporabnosti po prvem odprtju viale: 56 dni.
Substance P is found in significant concentrations in the nuclei comprising the emetic centre and is considered the key neurotransmitter involved in vomiting. 
Substanca P se v večjih koncentracijah nahaja v jedrih, ki sestavljajo center za bruhanje, in se šteje za ključni nevrotransmiter, udeležen pri bruhanju.
Marketing authorisation holder: Le Vet Beheer B.V. 
Imetnik dovoljenja za promet: Le Vet Beheer B.V.
Therefore, it is recommended to administer the veterinary medicinal product prior to administration of the chemotherapeutic agent. 
Zato je priporočljivo dajati zdravilo za uporabo v veterinarski medicini pred dajanjem kemoterapevtika.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary 
Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno)
QUANTITY OF THE ACTIVE SUBSTANCE(S) 10 mg/ml 
KOLIČINA UČINKOVIN(E) 10 mg/ml
PHARMACEUTICAL FORM Solution for injection A clear, colourless to light yellow solution 
FARMACEVTSKA OBLIKA raztopina za injiciranje bistra, brezbarvna do svetlo rumena raztopina
As the pharmacokinetic variation is large and maropitant accumulates in the body after once daily repeated administration, lower doses than recommended might be sufficient in some individuals and when repeating the dose. 
Zaradi velikega farmakokinetičnega razpona in kopičenja maropitanta v telesu po enkratni dnevni aplikaciji lahko pri nekaterih živalih in ob ponovitvi odmerka zadostujejo tudi nižji odmerki od priporočenih.
Do not use this veterinary medicinal product after the expiry date which is stated on the label of the vial after EXP. 
Tega zdravila za uporabo v veterinarski medicini ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na oznaki viale poleg oznake „Uporabno do“.
The elimination t1/2 following intravenous dosing was approximately 4.9 h. There appears to be an age-related effect on the pharmacokinetics of maropitant in cats with kittens having higher clearance than adults. 
Razpolovni čas izločanja t1/2 po intravenskem odmerjanju je bil približno 4,9 h. Kaže, da je farmakokinetika maropitanta odvisna od starosti živali, pri čemer je očistek pri mladih mačkah večji kot pri odraslih.
Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting. 
V skladu z dobro veterinarsko prakso bi bilo treba antiemetike uporabljati v povezavi z ostalimi veterinarskimi in podpornimi terapijami, kot sta dieta in tekočinska terapija, ter hkrati zdraviti osnovne vzroke bruhanja.
Pain at injection site may occur when injected subcutaneously. 
Bolečina na mestu injiciranja se lahko pojavi, če je zdravilo injicirano subkutano.
Maropitant undergoes cytochrome P450 (CYP) metabolism in the liver. 
Maropitant je podvržen presnovi s citokromom P450 (CYP) v jetrih.
Maropitant is highly bound to plasma proteins and may compete with other highly bound medicines. 
Maropitant se močno veže na plazemske proteine in lahko konkurira z ostalimi zdravili, ki se tudi močno vežejo.
In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician. 
V primeru nenamernega samoinjiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zunanji ovojnini.
Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed. 
Bruhanje je lahko povezano z resnimi stanji, ki žival močno izčrpajo, vključno z gastrointestinalnimi obstrukcijami, zato je treba postaviti pravilno diagnozo.
The anti-emetic efficacy of maropitant against central and peripheral emetics was demonstrated in experimental studies including apomorphine, cisplatin and syrup of ipecac (dogs) and xylazine (cats). 
V eksperimentalnih študijah je bila dokazana antiemetična učinkovitost maropitanta proti centralnim in perifernim emetikom, vključno z apomorfinom, cisplatinom in sirupom ipekakuanje (psi) in ksilazinom (mačke).
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products in the same syringe. 
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini v isti brizgi.
Amber glass type I vial closed with a coated bromobutyl rubber stopper and aluminium cap in a cardboard box. 
Steklena viala tipa I, jantarjeve barve, zaprta s klorobutilnim gumijastim zamaškom in aluminijastim pokrovčkom z zaporko v kartonski škatli.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs 
A. PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL) D. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
The safety of maropitant has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or lactating dogs and cats. 
Varnost maropitanta ni bila dokazana pri psih, mlajših od 8 tednov, mačkah, mlajših od 16 tednov, ter pri psicah in mačkah v obdobju brejosti in laktacije.
C. STATEMENT OF THE MRLs Not applicable. 
C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL) Navedba ni smiselna.
• For the treatment and prevention of nausea induced by chemotherapy. 
• Za zdravljenje in preprečevanje navzeje, povzročene zaradi kemoterapije
People with known hypersensitivity to maropitant should administer the veterinary medicinal product with caution. 
Osebe z znano preobčutljivostjo na maropitant naj zdravilo dajejo previdno.
In laboratory studies, maropitant has been shown to be a potential eye irritant. 
V laboratorijskih raziskavah se je izkazalo, da lahko maropitant draži oči.
CYP2D15 and CYP3A12 were identified as the canine isoforms involved in the hepatic biotransformation of maropitant. 
CYP2D15 in CYP3A12 sta pasji izoformi, vključeni v biotransformacijo maropitanta v jetrih.
The veterinary medicinal product should be used with caution in animals suffering from or with predisposition for cardiac diseases as maropitant has affinity to Ca- and K-ion channels. 
Posebna previdnost je potrebna pri uporabi zdravila pri živalih, ki so predisponirane za kardiološke bolezni, saj ima maropitant afiniteto do Ca- in K- ionskih kanalov.
Plasma protein binding of maropitant in dogs is more than 99%. 
Vezava maropitanta na plazemske proteine pri psih je več kot 99 %.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals, including isolated reports treated). 
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (pojavijo se pri več kot 1 živali od 10 zdravljenih živali in kažejo negativno(e) reakcijo(e)) - pogosti (pojavijo se pri več kot 1 a manj kot 10 živalih od 100 zdravljenih živali) - občasni (pojavijo se pri več kot 1 a manj kot 10 živalih od 1 000 zdravljenih živali) - redki (pojavijo se pri več kot 1 a manj kot 10 živalih od 10 000 zdravljenih živali) - zelo redki (pojavijo se pri manj kot 1 živali od 10 000 zdravljenih živali, vključujoč posamezne primere).
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription. 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Na veterinarski recept.
To prevent vomiting, Prevomax solution for injection should be administered more than 1 hour in advance. 
Za preprečevanje bruhanja dajemo Prevomax raztopino za injiciranje več kot eno uro vnaprej.
The bioavailability of maropitant after subcutaneous administration in dogs was 90.7%. 
Biorazpoložljivost maropitanta po subkutanem dajanju pri psih je 90,7 %.
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer responsible for batch release Produlab Pharma B.V. 
A. PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov proizvajalca, odgovornega za sproščanje serij Produlab Pharma B.V.
ATCvet code: QA04AD90 
Farmakoterapevtska skupina: antiemetiki Oznaka ATC vet: QA04AD90
The duration of effect is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis, e.g. chemotherapy. 
Učinek traja približno 24 ur, zato se lahko zdravilo da večer pred dajanjem zdravila, ki bi lahko povzročilo slabost, na primer pri kemoterapiji.
Renal clearance is a minor route of elimination, with less than 1% of a 1 mg/kg subcutaneous dose appearing in the urine as either maropitant or its major metabolite. 
Ledvični očistek predstavlja manjši delež izločanja, saj se manj kot 1 % subkutanega odmerka 1 mg/kg izloči z urinom kot maropitant ali njegov glavni presnovek.
The efficacy of maropitant in reduction of nausea in cats was demonstrated in studies using a model (xylazine-induced nausea). 
Učinkovitost maropitanta pri zmanjševanju navzeje pri mačkah so dokazali v študijah z uporabo modela (s ksilazinom povzročena navzea).
MARKETING AUTHORISATION NUMBER(S) 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET Z ZDRAVILOM
Vomiting can be associated with serious, severely debilitating conditions and the cause should be investigated. 
Bruhanje je lahko povezano z resnimi stanji, ki žival močno izčrpajo, in treba je najti vzrok.
The efficacy of maropitant in reduction of nausea was demonstrated in studies using a model (xylazine-induced nausea). 
Učinkovitost maropitanta pri zmanjševanju navzeje so dokazali v študijah z uporabo modela (s ksilazinom povzročena navzeja).
STATEMENT OF ACTIVE SUBSTANCES 10 mg/ml maropitant 
NAVEDBA UČINKOVIN 10 mg/ml maropitant
Prevomax should be used with caution in animals suffering from or with predisposition for heart diseases. 
Posebna previdnost je potrebna pri uporabi zdravila Prevomax pri živalih s potrjenimi boleznimi srca ali predispozicijo za bolezni srca.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) 
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (pojavijo se pri več kot 1 živali od 10 zdravljenih živali in kažejo negativno(e) reakcijo(e)) - pogosti (pojavijo se pri več kot 1 a manj kot 10 živalih od 100 zdravljenih živali) - občasni (pojavijo se pri več kot 1 a manj kot 10 živalih od 1 000 zdravljenih živali) - redki (pojavijo se pri več kot 1 a manj kot 10 živalih od 10 000 zdravljenih živali) - zelo redki (pojavijo se pri manj kot 1 živali od 10.000 živali, vključujoč posamezne primere).
TARGET SPECIES Dogs, cats 
CILJNE ŽIVALSKE VRSTE Psi, mačke
CYP1A and CYP3A-related enzymes were identified as the feline isoforms involved in the hepatic biotransformation of maropitant. 
CYP1A in encimi, povezani s CYP3A, so potrjeni kot mačje izoforme, vključene v biotransformacijo maropitanta v jetrih.
EXP Once broached use within 56 days. 
EXP Načeto zdravilo uporabite v 56 dneh.
Specific pharmacovigilance requirements: The PSURs for Prevomax shall be submitted at the same frequency as for Cerenia (reference product). 
Za zdravilo Prevomax se poročila PSUR predložijo v enakih intervalih kot za zdravilo Cerenia (referenčno zdravilo).
The use of Prevomax solution for injection against vomiting due to motion sickness is not recommended. 
Uporaba raztopine za injiciranje Prevomax za preprečevanje bruhanja zaradi vožnje ni priporočljiva.
Maropitant is metabolised in the liver and therefore should be used with caution in patients with hepatic disease. 
Maropitant se metabolizira v jetrih, zato je potrebna previdna uporaba pri živalih z jetrnimi obolenji.
The use of the veterinary medicinal product against vomiting due to motion sickness is not recommended. 
Uporaba zdravila za uporabo v veterinarski medicini proti bruhanju zaradi slabosti zaradi vožnje ni priporočljiva.
The bioavailability of maropitant after subcutaneous administration in cats was 91.3%. 
Biorazpoložljivost maropitanta po subkutanem dajanju pri mačkah je 91,3 %.
To prevent vomiting, the veterinary medicinal product solution for injection should be administered more than 1 hour in advance. 
Za preprečevanje se bruhanja daje zdravilo za uporabo v veterinarski medicini v obliki raztopine za injiciranje vsaj 1 uro vnaprej.